Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene
Stem Cell Research · 2023
DOI: 10.1016/j.scr.2023.103231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cell Research, 2023. Verfasst von Omer Hatim und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Alagille Syndrome, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, National Institutes of Health, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Alagille syndrome (ALGS) is an autosomal dominant, multisystemic disorder due to haploinsufficiency in either the JAG1 gene (ALGS type 1) or the NOTCH2 gene (ALGS type 2). The disease has been difficult to diagnose and treat due to its muti-system clinical presentation, variable expressivity, and prenatal onset for some of the features. The generation of this iPSC line (TRNDi032-A) carrying a heterozygous mutation, p.Cys682Leufs*7 (c.2044dup), in the JAG1 gene provides a means of studying the disease and developing novel therapeutics towards patient treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
- iPSC Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
- Transgenic Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
- Travere Therapeutics, 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA.
- Division of Genomic Diagnostics, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA. Electronic address: wzheng@mail.nih.gov.
Förderung
- Intramural NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
- Alagille Syndrome Alliance
Zitieren
APA
Hatim, O., Pavlinov, I., Xu, M., Linask, K., Beers, J., Liu, C., Baumgärtel, K., Gilbert, M., Spinner, N., Chen, C., Zou, J., & Zheng, W. (2023). Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene. Stem Cell Research. https://doi.org/10.1016/j.scr.2023.103231
Vancouver
Hatim O, Pavlinov I, Xu M, Linask K, Beers J, Liu C, et al. Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene. Stem Cell Research. 2023. doi:10.1016/j.scr.2023.103231
BibTeX
@article{Hatim2023,
author = {Hatim, Omer and Pavlinov, Ivan and Xu, Miao and Linask, Kaari and Beers, Jeanette and Liu, Chengyu and Baumgärtel, Karsten and Gilbert, Melissa and Spinner, Nancy and Chen, Catherine and Zou, Jizhong and Zheng, Wei},
title = {Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene},
journal = {Stem Cell Research},
year = {2023},
doi = {10.1016/j.scr.2023.103231}
}
EUVIMED